Shree Ganesh Remedies Ltd

- No explicit mention of any current or planned fundraising through debt or equity in the provided excerpts. - Discussion on capital expenditure (CAPEX) primarily focuses on Dahej and Ankleshwar plant expansions, with timelines for commissioning and commercialization mentioned. - Plans for NSE listing are under internal consideration but no specific timeline or active moves reported. - No disclosures on raising funds via equity or debt to support expansions or operations. - The company indicates plans for growth and capacity expansion but appears to rely on existing resources and operational cash flows. - If any fundraising plans arise, the management intends to discuss them with the board and announce subsequently.

- Current focus is on expansion at the Ankleshwar plant with the recently commissioned Unit 7A, expected to commission fully in the coming year. - Dahej plant's common utilities construction has started and is currently under construction. - Future expansion plans include the Dahej plant, which will commence after full utilization of the Ankleshwar unit. - Timeline for Dahej plant commercialization is approximately 16 to 20 months from start, expected to start after 1 year. - Block-7 expansion program is on track and expected to begin commercial production in Q2 FY27, supporting niche and application-led molecules including CRAMS. - Pilot facility commissioned earlier this year is fully operational, accelerating new product development. - No specific timelines given for NSE listing; discussions are ongoing with the board. - Capital expenditure for Unit-7 was around INR 34 crores, with an asset turnover ratio of about 1.8 to 2 at peak utilization.

- FY27 is expected to be a year where groundwork from FY26 translates into more visible business outcomes. - Block-7 expansion to begin commercial production in Q2 FY27, supporting niche and application-led molecules including CRAMS. - CRAMS projects are transitioning from pilot trials to commercial trials, with momentum expected to gradually improve through FY27. - CRAMS business anticipated to gain traction as the year progresses. - No significant revenue contribution from CRAMS expected in FY26; pilot approvals ongoing, commercial scale-up anticipated in coming years. - Base business is stable, operating in generic markets with limited growth, expected to plateau. - New projects selected from customers include a mix of CRAMS, specialty chemicals, and pharma; not focused solely on CRAMS. - Potential revenue from new CRAMS projects exists but timing and scale depend on customer approvals and market growth. - Peak utilization for manufacturing operations capped at 80-85%, supporting volume growth. - Asset turnover ratio around 1.8 to 2x expected at peak utilization.

- FY26 was a year of consolidation, focused on groundwork rather than aggressive top-line growth. - CRAMS projects have successfully completed pilot trials in FY26; commercial trials and production expected to begin in FY27. - FY27 anticipated as a year where groundwork translates into visible business outcomes with growth momentum improving gradually. - CRAMS business expected to gain traction as the year progresses, aiding structural growth beyond the INR 120 crore range. - Sustainable long-term EBITDA margin guidance is 26%-28%, with initial higher margins from newly approved CRAMS products. - Base business is stable with limited growth, while growth will largely come from scaling mid-size CRAMS projects. - Asset turnover at peak utilization is approximately 1.8 to 2 times. - Peak manufacturing utilization of 80%-85% possible leading to better revenue from new capacity expansions (Block-7 and Block-8). - Management optimistic of breaking growth plateau and moving towards 15-20% growth in coming years, subject to regulatory approvals and market conditions.

- The company has ongoing CRAMS projects with customers in Europe and Japan, with pilot trials successfully completed in Q4 FY26. - These projects are transitioning from pilot to commercial trials, pending customer and regulatory approvals. - There is no specific disclosure of orderbook size due to NDAs and competitive considerations. - The management refrains from giving project-specific revenue guidance but indicates a significant potential revenue contribution once approvals and commercialization progress. - The company expects commercial production from Block-7 expansion from Q2 FY27, supporting niche and application-led molecules including CRAMS projects. - Ramp-up and commercialization timelines depend on customer approvals, typically taking around 16 to 20 months for new plants like Dahej. - The CRAMS business is positioned for gradual growth over the next 2-3 years as projects gain traction and approvals advance.